Alliancebernstein L.P. trimmed its stake in Relx Plc (NYSE:RELX - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 903,242 shares of the technology company's stock after selling 38,247 shares during the period. Alliancebernstein L.P.'s holdings in Relx were worth $41,025,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership increased its stake in shares of Relx by 50.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company's stock worth $89,420,000 after acquiring an additional 658,655 shares in the last quarter. Natixis Advisors LLC increased its stake in shares of Relx by 2.8% in the 4th quarter. Natixis Advisors LLC now owns 1,202,592 shares of the technology company's stock worth $54,622,000 after acquiring an additional 32,739 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Relx in the 4th quarter worth about $44,516,000. JPMorgan Chase & Co. increased its stake in shares of Relx by 14.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company's stock worth $39,225,000 after acquiring an additional 104,999 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its stake in shares of Relx by 5.4% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 407,376 shares of the technology company's stock worth $18,503,000 after acquiring an additional 21,040 shares in the last quarter. 15.02% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
RELX has been the subject of a number of analyst reports. Barclays upgraded shares of Relx from an "equal weight" rating to an "overweight" rating in a research note on Friday, March 14th. The Goldman Sachs Group started coverage on shares of Relx in a research report on Wednesday, March 26th. They set a "buy" rating on the stock. StockNews.com cut shares of Relx from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Finally, Redburn Atlantic began coverage on shares of Relx in a research report on Wednesday, January 8th. They issued a "buy" rating on the stock. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy".
Get Our Latest Stock Analysis on Relx
Relx Trading Down 0.2 %
RELX stock traded down $0.07 during mid-day trading on Thursday, reaching $48.47. 247,774 shares of the stock traded hands, compared to its average volume of 721,653. The stock has a market capitalization of $89.95 billion, a PE ratio of 26.09, a PEG ratio of 2.73 and a beta of 0.84. Relx Plc has a one year low of $40.25 and a one year high of $51.99. The company has a debt-to-equity ratio of 1.46, a quick ratio of 0.47 and a current ratio of 0.52. The business has a 50-day moving average price of $49.32 and a two-hundred day moving average price of $47.86.
Relx Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be paid a $0.5586 dividend. The ex-dividend date of this dividend is Friday, May 9th. This is a positive change from Relx's previous semi-annual dividend of $0.23. This represents a yield of 1.6%. Relx's dividend payout ratio is 59.68%.
Relx Company Profile
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
See Also
Before you consider Relx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.
While Relx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
